Cyclerion Therapeutics CYCN
NASDAQ CYCN
$3.36 -0.85 (-20.19%)
At close: Sep 8, 2026 · 4:00 PM EDT

Cyclerion Therapeutics (CYCN) Income from Discontinued Operations (2022 - 2023)

Cyclerion Therapeutics (CYCN) posted Income from Discontinued Operations of $13.5 million for Q3 2023, up 666.61% on a QoQ basis from -$2.4 million in Q2 2023, and up 321.28% year-over-year from $3.2 million in Q3 2022.

Analysis

Cyclerion Therapeutics (CYCN) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

Cyclerion Therapeutics has reported Income from Discontinued Operations for 2 years, with the latest figure at $13.5 million in Q3 2023.

  • On a quarterly basis, Income from Discontinued Operations rose 321.28% year-over-year to $13.5 million in Q3 2023; TTM through Jun 2024 was $13.5 million, a 189.07% increase from a year earlier, with the FY2023 full-year figure at $7.3 million, up 128.38% from the prior year.
  • Income from Discontinued Operations was $13.5 million for Q3 2023 at Cyclerion Therapeutics, up from -$2.4 million in the prior quarter.
  • The five-year high for Income from Discontinued Operations was $13.5 million in Q3 2023, with the low at -$6.1 million in Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Amgen 207.17 Bn 193.18 Bn 7.24 Bn -
2 Gilead Sciences 179.52 Bn 176.34 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 131.47 Bn 123.62 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.73 Bn 73.74 Bn 3.93 Bn -
5 Argenx Se 61.16 Bn 55.98 Bn 1.37 Bn -
6 Moderna 53.28 Bn 48.14 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.06 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.65 Bn 30.37 Bn 1.96 Bn -
9 Roivant Sciences 29.30 Bn 29.30 Bn 1.16 Mn -
10 Cyclerion Therapeutics 15.70 Mn 12.46 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 13.47 Mn
Jun 30, 2023 -2.38 Mn
Mar 31, 2023 -3.77 Mn
Dec 31, 2022 -2.89 Mn
Sep 30, 2022 -6.09 Mn